Not sure if it was an oversight or misinterpretation, but ARX-04 is not up for being a prescription out of the hospital. I question how many times it would be dispensed in the hospital setting. Don't get me wrong, I think there is big potential and a lot of revenue to tap into, but the numbers, I believe, are skewed as many would not need opiods and for those who do, maybe one dose would be given?
Reading the latest report that the initial IV costs $145 or so, what is it in comparison to 04? Obviously the administering of the drug is near $0, but wondered what we are comparing price wise and what kind of savings the company is suggesting a hospital can save?
Though the number of patients is drastically lower, I believe the revenue for an UC drug that works well is pretty high. I thought the projected revenue for Uceris, bought by Salix from Santarus, was/is projected to top $1 billion annually in revenue.
With all of the worthless information on this board, it would be nice to see an actual discussion about something like this.
If you are looking for a buyout, it would seem the best strategy for maximizing the price of the company would be to shoot for a positive phase II trial in UC with Dolcanatide instead of a phase III for OIC. Seems to me with two indications of IBS and CIC, the drug would be prescribed off label anyways.
If he is keeping his shares and such, and getting a new gig, it makes all the sense in the world. Any other scenarios I will need more convincing that it isn't something to be concerned about.
Meanwhile, IRWD up 3% today, SGYP down 2.7%. As long as I have been in this stock, have to say, it really irritates me.
Analysts have consistently projected PT around $16-21. It is people on this board that project a BO of anywhere around $6-$10. I would like anything $13 and above, personally. Higher teens would be very nice.
I agree. I always thought it was kind of awkward that ARX-04 wasn't the front runner in the pipeline. Never made sense to me. Much less risk.
No.....I have been here since before the CRL and have stayed through it. Though I tend to look at the boards of various stocks I am in, it typically revolves around mindless conversations where one is either attacked for being a basher or a pumper. You followed through on that to a T. I'm just saying it is bothersome that you come out with a PR being a sub $1 company and don't mention the company name. Wait til the paper work is complete and come out with names and more info.
When they say, "A Global Pharmaceutical Company" instead of naming it, that makes me question integrity and honesty. I apologize if the company was actually named, but the PR did not mention any by name. Why? It makes no sense. I have been involved in other sub dollar companies where companies were not mentioned by name and it didn't go well.
I'm not a basher, just wanting clarification. What company is it? The deception in smaller companies is quite evident so why not name the actual company?
The biggest problem with your post is that you are leaving out that it is "A" Global Pharmaceutical company and not "the" Global Pharmaceutical company. Big difference. I think it is quite odd that they wouldn't state what company they are dealing with.
I hear ya. Crazy thing is, this was projected as a buyout target by Ram over two years ago. Just give me my $15 and let's call it a day.
Adam's great comeback.............wait for it....................wait for it......................"Protect your short position, Shorty!"
Pen, sometimes I think you give valuable information for people to consider. Other times, like this, I think you do yourself a disservice and end up making yourself look more foolish than anything.
I think the news is really a non factor. The drug has been proven to work well in multiple studies. Yes, it is good news, but it really isn't anything new that we already didn't know about the drug.
The only way this possibly goes to $45 at the bare minimum are incredible results from a Phase II UC Trial, which isn't coming anytime soon. There are many things that need to happen. Most likely product gets bought out, most likely at a price of $15-$22. If you had good results supporting Dolcanatide's use in the prevention of Colon Cancer, than I think you could up your price. :-)
Jim, classy response and thanks for understanding my position. That's all I would like, some dialogue and ability to talk about some issues of concern as well as great things the company has going for them.
Smh......soft bashing? I may be critical of a company's decision at times and the decisions revolving around ACRX have been questionable at best. It's unfortunate that one can't utilize message boards to gain insight into a company without being told everything is great or everything is bad. People like you consider those that are in the middle, "bashers". Keep on pumping away as I guess the world needs ditch diggers, too.